SlowMo, a digital therapy targeting reasoning in paranoia, versus treatment as usual in the treatment of people who fear harm from others: study protocol for a randomised controlled trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Paranoia is one of the most common symptoms of schizophrenia-spectrum disorders, and is associated with significant distress and disruption to the person's life. Developing more effective and accessible psychological interventions for paranoia is a clinical priority. Our research team has approached this challenge in two main ways: firstly, by adopting an interventionist causal approach to increase effectiveness and secondly, by incorporating user-centred inclusive design methods to enhance accessibility and usability. Our resultant new digital intervention, SlowMo, intensively targets a reasoning style associated with paranoia, fast thinking, characterised by jumping to conclusions and belief inflexibility. It consists of an easy-to-use, enjoyable and memorable digital interface. An interactive web-based app facilitates delivery of face-to-face meetings which is then synchronised with an innovative mobile app for use in daily life. METHODS/DESIGN: We aim to test the clinical efficacy of SlowMo over 24 weeks to determine the mechanisms through which it reduces paranoia, and to identify participant characteristics that moderate its effectiveness. In a parallel-group randomised controlled trial, with 1:1 allocation, 360 participants with distressing persecutory beliefs will be independently randomised to receive either the SlowMo intervention added to treatment as usual (TAU) or TAU, using randomly varying permuted blocks, stratified by paranoia severity and site. Research workers will be blind to therapy allocation. The primary outcome is paranoia severity over 24 weeks; our hypothesised mechanism of change is reasoning; moderators include negative symptoms and working memory; and secondary outcomes include wellbeing, quality of life, and service use. The accessibility, usability and acceptability of the digital platform will be assessed. DISCUSSION: SlowMo has been developed as the first blended digital therapy to target fears of harm from others through an inclusive design approach. In addition to testing its efficacy, this trial will add to our understanding of psychological mechanisms in paranoia. The study will examine the usability and adherence of a novel digital therapy, including an app for self-management, in a large sample of people affected by severe mental health difficulties. TRIAL REGISTRATION: ISRCTN registry, ID: ISRCTN32448671 . Registered prospectively on 30 January 2017. Date assigned 2 February 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
HADDOCK, G., McCARRON, J., TARRIER, N., & FARAGHER, E. B. (1999) · Psychological Medicine · doi:10.1017/s0033291799008661 · Cited by 1,461 · cited 1×
“The Psychotic Symptom Rating Scales-Delusions (PSYRATS-Delusions; [44]), consisting of six items”
MethodApplication and Results of the Manchester Short Assessment of Quality of Life (Mansa)
Priebe, S., Huxley, P., Knight, S., & Evans, S. (1999) · International Journal of Social Psychiatry · doi:10.1177/002076409904500102 · Cited by 1,071 · cited 1×
“3 for details of secondary outcomes and other key processes hypothesised as moderators; these include published and established measures of wellbeing [49], quality of life [50], self and other schemas [51], service use [43], worry [52], cognitive tests [45, 53–55], other paranoia measures [56] and measures of beliefs…”
BackgroundPsychological investigation of the structure of paranoia in a non-clinical population
Freeman, D., Garety, P. A., Bebbington, P. E., Smith, B., Rollinson, R., Fowler, D., Kuipers, E., Ray, K., & Dunn, G. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.5.427 · Cited by 786
Self-citationAgarwal, S., LeFevre, A. E., Lee, J., L’Engle, K., Mehl, G., Sinha, C., & Labrique, A. (2016) · BMJ · doi:10.1136/bmj.i1174 · Cited by 639 · cited 1×
“org/) Statement will be followed, with consideration of the mHealth evidence reporting and assessment (mERA) [37] and CONSORT-EHEALTH Checklists [38].”
MethodFeasibility, Acceptability, and Preliminary Efficacy of a Smartphone Intervention for Schizophrenia
Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., & Mueser, K. T. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu033 · Cited by 493
FOWLER, D., FREEMAN, D., SMITH, B., KUIPERS, E., BEBBINGTON, P., BASHFORTH, H., COKER, S., HODGEKINS, J., GRACIE, A., DUNN, G., et al. (2006) · Psychological Medicine · doi:10.1017/s0033291706007355 · Cited by 476
Self-citationGreen, C. E. L., Freeman, D., Kuipers, E., Bebbington, P., Fowler, D., Dunn, G., & Garety, P. A. (2008) · Psychological Medicine · doi:10.1017/s0033291707001638 · Cited by 401 · cited 7×
“The inclusion criteria are as follows: aged 18 years and over; persistent (3 + months) distressing paranoia (as assessed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN, [40]) and scoring > 29 on the GPTS, part B, persecutory subscale [36]; diagnosis of schizophrenia-spectrum psychosis (F20-29, IC…”
MethodInfluentialLinden, M. (2013) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.1765 · Cited by 397 · cited 1×
“Following [59], the event will then be rated within five categories from ‘not related’ to ‘related’.”
BackgroundTechnological innovations in mental healthcare: harnessing the digital revolution
Hollis, C., Morriss, R., Martin, J., Amani, S., Cotton, R., Denis, M., & Lewis, S. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.142612 · Cited by 375
Cited by
The digital revolution and its impact on mental health care
Bucci, S., Schwannauer, M., & Berry, N. (2019) · Psychology and Psychotherapy: Theory, Research and Practice · doi:10.1111/papt.12222 · Cited by 444
Freeman, D., Loe, B. S., Kingdon, D., Startup, H., Molodynski, A., Rosebrock, L., Brown, P., Sheaves, B., Waite, F., & Bird, J. C. (2021) · Psychological Medicine · doi:10.1017/s0033291719003155 · Cited by 288
Self-citationSmartphone Apps for the Treatment of Mental Disorders: Systematic Review
Miralles, I., Granell, C., Díaz-Sanahuja, L., Van Woensel, W., Bretón-López, J., Mira, A., Castilla, D., & Casteleyn, S. (2020) · JMIR mHealth and uHealth · doi:10.2196/14897 · Cited by 188
“iCOPE [92], MindFrame [93], movisenseXS [94], RealLife Exp [95], SlowMo [96], TechCare [97], Temstem [98], Actissist [99,100], FOCUS [101,102], Heal Your Mind [103], PRIME [104,105] Schizophrenia spectrum and other psychotic disorders”
BackgroundTreatable clinical intervention targets for patients with schizophrenia
Freeman, D., Taylor, K. M., Molodynski, A., & Waite, F. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.016 · Cited by 125
Self-citationAllan, S., Bradstreet, S., Mcleod, H., Farhall, J., Lambrou, M., Gleeson, J., Clark, A., EMPOWER Group, & Gumley, A. (2019) · Journal of Medical Internet Research · doi:10.2196/14366 · Cited by 44
“Digital interventions can help address clinical priorities in psychosis, such as increasing access to psychological interventions for symptoms such as paranoia [14].”
Background
Metadata
- Authors
- Garety, P. A., Ward, T., Freeman, D., Fowler, D., Emsley, R., Dunn, G., Kuipers, E., Bebbington, P., Waller, H., Greenwood, K., Rus-Calafell, M., McGourty, A., & Hardy, A.
- Venue
- Trials
- Published
- 2017-11-02
- Volume
- 18
- Issue
- 1
- Pages
- 510-510
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2767101694
- Cited by
- 66
- References
- 26
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SlowMo, a digital therapy targeting reasoning in paranoia, versus treatment as usual in the treatment of people who fear harm from others: study protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-017-2242-7
- The paper
- Garety, P. A., Ward, T., Freeman, D., Fowler, D., Emsley, R., Dunn, G., Kuipers, E., Bebbington, P., Waller, H., Greenwood, K., Rus-Calafell, M., McGourty, A., & Hardy, A. (2017). SlowMo, a digital therapy targeting reasoning in paranoia, versus treatment as usual in the treatment of people who fear harm from others: study protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-017-2242-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.